Baker Chad R Reduces Holdings in Stryker Corporation $SYK

Baker Chad R lowered its position in shares of Stryker Corporation (NYSE:SYK) by 9.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,960 shares of the medical technology company’s stock after selling 1,955 shares during the period. Baker Chad R’s holdings in Stryker were worth $6,714,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in Stryker by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock worth $12,485,012,000 after buying an additional 272,828 shares during the last quarter. State Street Corp lifted its stake in Stryker by 1.0% in the second quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock valued at $5,929,765,000 after buying an additional 150,204 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after buying an additional 741,542 shares during the last quarter. Norges Bank acquired a new stake in shares of Stryker in the second quarter valued at approximately $1,882,173,000. Finally, Legal & General Group Plc grew its position in shares of Stryker by 4.4% during the third quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock worth $851,457,000 after acquiring an additional 96,662 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Performance

NYSE:SYK opened at $332.58 on Friday. The firm’s fifty day moving average price is $360.91 and its 200 day moving average price is $364.35. Stryker Corporation has a 1-year low of $324.93 and a 1-year high of $404.87. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The firm has a market cap of $127.37 billion, a price-to-earnings ratio of 39.59, a price-to-earnings-growth ratio of 1.92 and a beta of 0.85.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the prior year, the firm earned $4.01 EPS. Stryker’s quarterly revenue was up 11.4% on a year-over-year basis. On average, sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio is currently 41.90%.

Analyst Ratings Changes

A number of equities analysts have recently commented on SYK shares. Evercore set a $390.00 target price on shares of Stryker in a report on Monday, January 5th. Robert W. Baird set a $437.00 price objective on shares of Stryker in a research report on Friday, January 30th. Needham & Company LLC lifted their price objective on shares of Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research note on Friday, January 30th. William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Finally, Sanford C. Bernstein increased their target price on shares of Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Fourteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $427.50.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.90% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.